P N Munster

Summary

Affiliation: University of South Florida
Country: USA

Publications

  1. pmc Predictive factor for the response to adjuvant therapy with emphasis in breast cancer
    P N Munster
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Breast Cancer Res 3:361-4. 2001
  2. ncbi request reprint In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates
    Douglas C Marchion
    Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive SRB 22007, Tampa, FL 33612, USA
    Mol Cancer Ther 4:1993-2000. 2005
  3. ncbi request reprint Arzoxifene: the development and clinical outcome of an ideal SERM
    Pamela N Munster
    Interdisciplinary Oncology Program, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Expert Opin Investig Drugs 15:317-26. 2006
  4. ncbi request reprint Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway
    Pamela N Munster
    Interdisciplinary Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12901 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Res 62:3132-7. 2002
  5. ncbi request reprint Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor
    P N Munster
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 7:2228-36. 2001
  6. ncbi request reprint The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells
    P N Munster
    Program in Cell Biology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 61:8492-7. 2001
  7. ncbi request reprint Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases
    F F Zheng
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 60:2090-4. 2000
  8. ncbi request reprint Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells
    P N Munster
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 61:2945-52. 2001
  9. ncbi request reprint A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells
    G Chiosis
    Program in Cell Biology and Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Chem Biol 8:289-99. 2001
  10. ncbi request reprint Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer
    P N Munster
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:2002-9. 2001

Research Grants

Detail Information

Publications23

  1. pmc Predictive factor for the response to adjuvant therapy with emphasis in breast cancer
    P N Munster
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Breast Cancer Res 3:361-4. 2001
    ..These include HER2, p53 and Bcl-2, cathepsin B, p27, proliferating cell nuclear antigen (PCNA), cyclin D, Ki-67, and vascular endothelial growth factor (VEGF)...
  2. ncbi request reprint In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates
    Douglas C Marchion
    Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive SRB 22007, Tampa, FL 33612, USA
    Mol Cancer Ther 4:1993-2000. 2005
    ..Ex vivo comet assays may be useful as a predictive tool when tumor cells are limited and serial biopsies are difficult to obtain...
  3. ncbi request reprint Arzoxifene: the development and clinical outcome of an ideal SERM
    Pamela N Munster
    Interdisciplinary Oncology Program, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Expert Opin Investig Drugs 15:317-26. 2006
    ..HCl) meets all of these criteria. This review summarises the development, preclinical studies and the clinical outcome of arzoxifene and places it in context with other modalities in the treatment of hormone receptor-positive tumours...
  4. ncbi request reprint Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway
    Pamela N Munster
    Interdisciplinary Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12901 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Res 62:3132-7. 2002
    ..These observations have important clinical implications because they may help to identify patients that are most likely to benefit from 17-AAG and may explain resistance to Herceptin as seen in many patients...
  5. ncbi request reprint Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor
    P N Munster
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 7:2228-36. 2001
    ..These findings suggest that inhibition of Hsp90 function by 17-AAG enhances the apoptotic effects of cytotoxic agents. The sequence of drug administration and the RB status significantly influence efficacy...
  6. ncbi request reprint The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells
    P N Munster
    Program in Cell Biology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 61:8492-7. 2001
    ..SAHA and other HDAC inhibitors are currently in Phase I clinical trials. These findings may impact the clinical use of these drugs...
  7. ncbi request reprint Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases
    F F Zheng
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 60:2090-4. 2000
    ..GMD-4c could be useful in the treatment of carcinomas dependent on HER-kinases...
  8. ncbi request reprint Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells
    P N Munster
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 61:2945-52. 2001
    ..G1 arrest is sufficient for some but not all aspects of the phenotype. Induction of differentiation may be responsible for some of the antitumor effects of this drug...
  9. ncbi request reprint A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells
    G Chiosis
    Program in Cell Biology and Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Chem Biol 8:289-99. 2001
    ..e. steroid receptors, Her2, Raf). We have used the structural features of this pocket to design a small molecule inhibitor of Hsp90...
  10. ncbi request reprint Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer
    P N Munster
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:2002-9. 2001
    ..HCl-a novel, potent, third-generation selective estrogen receptor modulator (SERM)-because this benzothiophene derivative demonstrated an SERM profile in preclinical studies...
  11. ncbi request reprint Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety
    Feng Guo
    Department of Oncology, Pfizer Global Research and Development, 50 Pequot Avenue MS6025 A3238, New London, CT 06320, USA
    Cancer Chemother Pharmacol 62:97-109. 2008
    ....
  12. ncbi request reprint Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta
    Douglas C Marchion
    Experimental Therapeutics Program, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 11:8467-75. 2005
    ..Histone deacetylase inhibitors (HDACi) are a novel class of compounds that potentiate the antitumor effects of topoisomerase II-targeting agents...
  13. ncbi request reprint Valproic acid alters chromatin structure by regulation of chromatin modulation proteins
    Douglas C Marchion
    Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer Res 65:3815-22. 2005
    ..The proposed mechanism of action suggests an effect of drug sequencing on the antitumor activity of these drugs...
  14. ncbi request reprint Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid
    Douglas C Marchion
    Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Cell Biochem 92:223-37. 2004
    ..These findings may impact the clinical development of combining HDAC inhibitors with DNA damaging agents...
  15. ncbi request reprint Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer
    Aman Buzdar
    M D Anderson Cancer Center and US Oncology Research, Houston, and Baylor Sammons Cancer Center and Texas Oncology, Dallas, TX 77030, USA
    J Clin Oncol 21:1007-14. 2003
    ....
  16. ncbi request reprint Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer
    Susan E Minton
    Comprehensive Breast Cancer Program, H Lee Moffitt Cancer Center Research Institute, Tampa, Florida 33612, USA
    Cancer Control 9:466-72. 2002
    ..The majority of women diagnosed with early-stage breast cancer have an excellent long-term prognosis, but many will undergo temporary or permanent chemotherapy-induced amenorrhea...
  17. ncbi request reprint Improving breast cancer care
    Pamela N Munster
    Cancer Control 9:455-6. 2002
  18. pmc Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2
    Andrea D Basso
    Program in Pharmacology, Weill Graduate School of Medical Sciences, Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Oncogene 21:1159-66. 2002
    ..Thus, pharmacological inhibition of Akt activation is achievable with ansamycins and may be useful for the treatment of HER2 driven tumors...
  19. pmc Fatigue after treatment for early stage breast cancer: a controlled comparison
    Paul B Jacobsen
    Health Outcomes and Behavior Program, Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer 110:1851-9. 2007
    ..The present study sought to determine whether fatigue was greater in women who had completed treatment for early-stage breast cancer relative to a demographically matched comparison group of women with no cancer history...
  20. ncbi request reprint First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors
    Pamela N Munster
    Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 13:1238-45. 2007
    ..To test the tolerability, safety, and recommended phase II dose of CP-724,714, a reversible, highly selective, oral HER2 tyrosine kinase inhibitor in patients with advanced solid tumor malignancies that express HER2...
  21. ncbi request reprint Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial
    George R Simon
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, SRB 2, Tampa, 33612 9416, USA
    Mol Cancer Ther 5:2130-7. 2006
    ..Here, we evaluated a sequence-specific administration of a topo I inhibitor followed by a topo II inhibitor...
  22. ncbi request reprint Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database
    M Aleem Khan
    Department of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 13:211-7. 2006
    ..Since few trials in melanoma have had a non-treated cohort, it remains unclear what survival can be expected in patients who are not treated with chemotherapy...
  23. ncbi request reprint Physical symptoms/side effects during breast cancer treatment predict posttreatment distress
    Heather S Jim
    Health Outcomes and Behavior Program, H Lee Moffitt Cancer Center, University of South Florida, Tampa, FL 33612, USA
    Ann Behav Med 34:200-8. 2007
    ..Studies suggest that the period following completion of treatment can be distressing for cancer patients. One potentially important predictor of distress is physical symptoms/side effects during treatment...

Research Grants3

  1. Potentiation of Topo Inhibitors by HDAC Inhibitors
    Pamela Munster; Fiscal Year: 2005
    ..Finally, the utility of the topo II inhibitors could be enhanced if their efficacy could be increased without worsening toxicity, as our preclinical data appears to indicate. ..
  2. Potentiation of Topo Inhibitors by the HDACi, SAHA
    Pamela Munster; Fiscal Year: 2007
    ..These findings may be useful in the rational design of future clinical trials involving HDACi. ..
  3. The Role of Selective HDAC Enzymes in Drug Sensitivity
    Pamela Munster; Fiscal Year: 2007
    ..In pre- and post-treatment tumor samples, we will determine which HDACs are involved in the cellular effects induced by the HDACi and which HDACs may predict response. ..